| Authors: |
Pearson AD; ACCELERATE, Europe. Electronic address: andy1pearson@btinternet.com., Gaspar N; Gustave Roussy Cancer Centre, Paris, France., Janeway K; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA., Campbell-Hewson Q; Great North Children's Hospital, Newcastle, UK., Lawlor ER; Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA., Copland C; ACCELERATE, Europe; Euro Ewings Consortium, Europe, UK., Karres D; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Netherlands., Norga K; Antwerp University Hospital, Antwerp, Belgium; Paediatric Committee of the European Medicines Agency (EMA), Netherlands; Federal Agency for Medicines and Health Products, Belgium., Benzaghou F; Ipsen Pharma, Cambridge, MA, USA., Weiner S; Children's Cancer Cause, USA., Weigel B; University of Minnesota, Minneapolis, USA., Weiss AR; Maine Medical Center, Portland, ME, USA., Strauss SJ; University College London, London, UK., Smith M; National Cancer Institute, USA., Setty BA; Division of Pediatric Hematology/Oncology/Bone Marrow Transplantation, Nationwide Children's Hospital, Columbus, OH, USA., Seibel N; National Cancer Institute, USA., Scobie N; Zoe4Life, Switzerland., Pappo A; St Jude Children's Research Hospital, USA., Okpara CE; Eisai GmbH, Frankfurt, Germany., Nysom K; Righospitalet, Denmark., McDonough J; The Andrew McDonough B+ Foundation, USA., Marshall LV; The Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK., Ludwinski D; Solving Kids' Cancer, USA., Ligas F; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Netherlands., Lesa G; Paediatric Medicines Office, Scientific Evidence Generation Department, Human Division, European Medicines Agency (EMA), Netherlands., Knudsen S; Allarity Therapeutics, MA, USA., Kauh J; HUTCHMED International Corporation, USA., Hsieh A; Blueprint Medicines, Boston, MA, USA., Heenen D; KickCancer, Belgium., Hawkins DS; Seattle Children's Hospital, USA; Children's Oncology Group, USA., Graham A; MIB Agents, Osteosarcoma Alliance, USA., Garmey E; Oncoheroes Biosciences, Boston, MA, USA., DuBois SG; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA., Fox E; St Jude Children's Research Hospital, USA., Donoghue M; US Food and Drug Administration, USA., de Rojas T; ACCELERATE, Europe., Chung J; Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA., Casanova M; Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Brennan B; Royal Manchester Children's Hospital, Manchester, UK., Bishop M; St Jude Children's Research Hospital, USA., Buenger V; Coalition Against Childhood Cancer (CAC2), USA., Reaman G; US Food and Drug Administration, USA., Vassal G; ACCELERATE, Europe; Gustave Roussy Cancer Centre, Paris, France. |
